Merck to buy privately-held Peloton Therapeutics
Merck & Co Inc says it is buying Peloton Therapeutics Inc for $1.05 billion in cash plus $1.15 billion in additional payments based on how the company's drugs fare once they are further developed. The purchase will give it access to the privately held company’s lead kidney cancer drug candidate.
Peloton had said earlier this month that it was planning to raise up to $159.4 million in an initial public offering. That offering was set to begin trading publicly on Wednesday.
MRK sees its Stochastic Oscillator recovers from oversold territory
On November 30, 2023, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 49 instances where the indicator left the oversold zone. In of the 49 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 30, 2023. You may want to consider a long position or call options on MRK as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on November 30, 2023. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
MRK moved above its 50-day moving average on December 01, 2023 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRK broke above its upper Bollinger Band on December 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRK entered a downward trend on December 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 70, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.154) is normal, around the industry mean (5.167). P/E Ratio (55.556) is within average values for comparable stocks, (34.789). Projected Growth (PEG Ratio) (0.803) is also within normal values, averaging (3.111). Dividend Yield (0.029) settles around the average of (0.029) among similar stocks. P/S Ratio (4.305) is also within normal values, averaging (3.583).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | +0.96% | ||
| NVS - MRK | 50% Loosely correlated | +0.23% | ||
| JNJ - MRK | 47% Loosely correlated | +2.41% | ||
| GILD - MRK | 43% Loosely correlated | +1.37% | ||
| LLY - MRK | 36% Loosely correlated | -1.18% | ||
| ABBV - MRK | 34% Loosely correlated | +0.72% | ||
More | ||||